Ruth M. O’Regan, MD, and Douglas Yee, MD: Results From the I-SPY2 Trial

Posted: Thursday, December 7, 2017

Ruth M. O’Regan, MD, of the University of Wisconsin Carbone Cancer Center, and Douglas Yee, MD, of the Masonic Cancer Center, University of Minnesota, discuss study findings that showed pathologic complete response predicts event-free and distant disease–free survival.